NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Sun X, Patnode CD, Williams C, et al. Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Dec. (Comparative Effectiveness Reviews, No. 91.)
This publication is provided for historical reference only and the information may be out of date.
Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness [Internet].
Show details- 1.
- Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47–52. [PMC free article: PMC1415841] [PubMed: 16614742]
- 2.
- Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011 Sep;31(8):1090–101. [PubMed: 21745274]
- 3.
- Centers for Disease Control and Prevention. Viral Hepatitis Surveillance - United States. 2009. 2011. http://www
.cdc.gov/hepatitis /Statistics/index.htm. - 4.
- Smith BC, Morgan RL, Beckett G, et al. Recommendations for the Identification of Hepatitis C Virus (HCV) Chronic Infection Among Persons Born During 1945 through 1965. Atlanta, GA: Centers for Disease Control and Prevention; 2012. [draft for public comment]
- 5.
- Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 May 16;144(10):705–14. [PubMed: 16702586]
- 6.
- Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012 Feb 21;156(4):271–8. [PubMed: 22351712]
- 7.
- Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011 Aug 13;378(9791):571–83. [PMC free article: PMC3285467] [PubMed: 21802134]
- 8.
- Rifai MA, Gleason OC, Sabouni D. Psychiatric care of the patient with hepatitis C: a review of the literature. Prim Care Companion. J Clin Psychiatry. 2010;12(6) [PMC free article: PMC3067984] [PubMed: 21494349]
- 9.
- Higgs P, Sacks-Davis R, Gold J, et al. Barriers to receiving hepatitis c treatment for people who inject drugs myths and evidence. Hepatitis Monthly. 2011;11(7):513–8. [PMC free article: PMC3212767] [PubMed: 22087188]
- 10.
- Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv. 2006 Apr;57(4):570–2. [PubMed: 16603757]
- 11.
- Centers for Disease Control. Morbidity and Mortality Weekly Report. May 22, 2009. pp. 1–27. [PubMed: 19478727]
- 12.
- Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, Md ). 2009 Apr;49(4):1335–74. [PMC free article: PMC7477893] [PubMed: 19330875]
- 13.
- Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008 Jul 26;372(9635):321–32. [PubMed: 18657711]
- 14.
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10–12, 2002). Gastroenterology. 2002 Dec;123(6):2082–99. [PubMed: 12454863]
- 15.
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825–32. [PubMed: 9121257]
- 16.
- Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004 Feb;12(2):96–102. [PubMed: 15036326]
- 17.
- Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology. 2006 Aug;131(2):478–84. [PubMed: 16890602]
- 18.
- Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996 Oct 15;125(8):634–9. [PubMed: 8849147]
- 19.
- Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat. 2001 Mar;8(2):87–95. [PubMed: 11264728]
- 20.
- Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol. 2000 Feb;38(2):575–7. [PMC free article: PMC86151] [PubMed: 10655348]
- 21.
- Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002 May;122(6):1554–68. [PubMed: 12016423]
- 22.
- Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007 Feb 21;297(7):724–32. [PubMed: 17312292]
- 23.
- Gebo KA, Bartlett JG. Management of hepatitis C: a review of the NIH Consensus Development Conference. The Hopkins HIV Report: a Bimonthly Newsletter for Healthcare Providers. 2002 Sep;14(5):suppl i–iv. [PubMed: 12240644]
- 24.
- Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010 Apr;51(4):1176–84. [PubMed: 20187106]
- 25.
- Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis. C Cochrane Database Syst Rev. 2010;(1):CD005445. [PubMed: 20091577]
- 26.
- Parikh M, Singh A, Sood G. Extended treatment duration for treatment naive chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin. J Viral Hepat. 2011 Apr;18(4):e99–103. [PubMed: 20950407]
- 27.
- Zhao S, Liu E, Chen P, et al. A comparison of peginterferon alpha-2a and alpha-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials. Clin Ther. 2010 Aug;32(9):1565–77. [PubMed: 20974315]
- 28.
- Fabrizi F, Dixit V, Martin P, et al. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2011 Jul;18(7):e263–e269. [PubMed: 21108701]
- 29.
- D’Heygere F, George C, Van VH, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol. 2011 May;83(5):815–9. [PubMed: 21412790]
- 30.
- Agency for Healthcare Research and Quality. ’s Effective Health Care Program. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review (draft report). Forthcoming 2012.
- 31.
- Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Oct 1;54(4):1433–44. [PMC free article: PMC3229841] [PubMed: 21898493]
- 32.
- Tanioka D, Iwasaki Y, Araki Y, et al. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient’s motivation and physician’s treatment experience. Liver International. 2009 May;29(5):721–9. [PubMed: 19141025]
- 33.
- Satapathy SK, Lingisetty CS, Proper S, et al. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol. 2010 Feb;44(2):140–5. [PubMed: 19826275]
- 34.
- Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009 Jan 15;360(3):257–67. [PubMed: 19144941]
- 35.
- Evon DM, Ramcharran D, Belle SH, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. American Journal of Gastroenterology. 2009 Dec;104(12):2949–58. [PubMed: 19789525]
- 36.
- Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006 May;130(6):1607–16. [PubMed: 16697724]
- 37.
- Chu CJ, Lee SD, Hung TH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther. 2009 Jan;29(1):46–54. [PubMed: 18680550]
- 38.
- Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006 Aug;131(2):470–7. [PubMed: 16890601]
- 39.
- McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002 Oct;123(4):1061–9. [PubMed: 12360468]
- 40.
- Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am. 2004 Mar;33(Suppl 1):11–24. [PubMed: 15081100]
- 41.
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975–82. [PubMed: 12324553]
- 42.
- Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124(6):1711–9. [PubMed: 12761728]
- 43.
- Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17;461(7262):399–401. [PubMed: 19684573]
- 44.
- Lo Re V, Teal V, Localio AR, et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med. 2011 Sep 20;155(6):353–60. [PMC free article: PMC3366635] [PubMed: 21930852]
- 45.
- Weiss JJ, Brau N, Stivala A, et al. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Alimentary Pharmacology & Therapeutics. 2009 Jul;30(1):14–27. [PMC free article: PMC3102513] [PubMed: 19416131]
- 46.
- Beste LA, Ioannou GN, Larson MS, et al. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clinical Gastroenterology & Hepatology. 2010 Nov;8(11):972–8. [PubMed: 20692371]
- 47.
- Martin-Santos R, Diez-Quevedo C, Castellvi P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology & Therapeutics. 2008 Feb 1;27(3):257–65. [PubMed: 17988237]
- 48.
- Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003 Feb;37(2):443–51. [PubMed: 12540795]
- 49.
- Marcellin P, Chousterman M, Fontanges T, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver International. 2011 Apr;31(4):516–24. [PubMed: 21382162]
- 50.
- Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. European Journal of Gastroenterology & Hepatology. 2007 Sep;19(9):741–7. [PubMed: 17700258]
- 51.
- Cournot M, Glibert A, Castel F, et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterologie Clinique et Biologique. 2004 Jun;28(6–7 Pt 1):533–9. [PubMed: 15243385]
- 52.
- Wilkinson M, Crawford V, Tippet A, et al. Community-based treatment for chronic hepatitis C in drug users: High rates of compliance with therapy despite ongoing drug use. Alimentary Pharmacology and Therapeutics. 2009;29(1):29–37. [PubMed: 18752631]
- 53.
- Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011 Aug;34(3):297–305. [PubMed: 21623851]
- 54.
- Evon DM, Esserman DA, Ramcharran D, et al. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. Journal of Psychosomatic Research. 2011 Nov;71(5):349–56. [PMC free article: PMC3197215] [PubMed: 21999979]
- 55.
- Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract. 2009 Jan;15(1):34–44. [PubMed: 19182563]
- 56.
- Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008 Jan;11(1):44–7. [PubMed: 18237359]
- 57.
- Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008 [PubMed: 18425859]
- 58.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002 Dec 11;288(22):2868–79. [PubMed: 12472329]
- 59.
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487–97. [PubMed: 16079372]
- 60.
- Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clinical Drug Investigation. 2008;28(1):9–16. [Erratum appears in Clin Drug Investig. 2008;28(4):210] [PubMed: 18081356]
- 61.
- Bertino G, Ardiri A, Boemi PM, et al. Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. European Journal of Clinical Pharmacology. 2010 Oct;66(10):1055–63. [PubMed: 20652232]
- 62.
- Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996 Jun;8(3):261–9. [PubMed: 8827119]
- 63.
- Sola R, Galeras JA, Montoliu S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Research & Human Retroviruses. 2006 May;22(5):393–400. [PubMed: 16706615]
- 64.
- Bonkovsky HL, Tice AD, Yapp RG, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. American Journal of Gastroenterology. 2008 Nov;103(11):2757–65. [PubMed: 18684176]
- 65.
- Cohen SM, Kwasny MJ, Ahn J. Use of specialty care versus standard retail pharmacies for treatment of hepatitis C. Ann Pharmacother. 2009 Feb;43(2):202–9. [PubMed: 19193591]
- 66.
- Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int. 2009 Jan;29(Suppl 1):15–8. [PubMed: 19207961]
- 67.
- Chou R, Clark EC, Helfand M. Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventative Services Task Force. Ann Intern Med. 2004;140(6):465–79. [PubMed: 15023713]
- 68.
- Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2002 Sep;16(9):1633–9. [PubMed: 12197842]
- 69.
- Hassan Y, Al-Jabi SW, Aziz NA, et al. Antiplatelet therapy in diabetic ischemic stroke patients: associated factors and outcomes. Int J Clin Pharmacol Ther. 2011 Oct;49(10):605–13. [PubMed: 21961485]
- 70.
- Rodgers PT, Ruffin DM. Medication nonadherence: Part II--A pilot study in patients with congestive heart failure. Manag Care Interface. 1998 Sep;11(9):67–9. 75. [PubMed: 10187590]
- 71.
- Misdrahi D, Llorca PM, Lancon C, et al. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications]. Encephale. 2002 May;28(3 Pt 1):266–72. [PubMed: 12091789]
- 72.
- Sasadeusz JJ, Dore G, Kronborg I, et al. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction (Abingdon, England). 2011;106(5):977–84. [PubMed: 21205057]
- 73.
- Foster GR, Fried MW, Hadziyannis SJ, et al. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scandinavian Journal of Gastroenterology. 2007 Feb;42(2):247–55. [PubMed: 17327945]
- 74.
- Dahlan Y, Ather HM, Al-ahmadi M, et al. Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population. World Journal of Gastroenterology. 2009 Sep 21;15(35):4429–33. [PMC free article: PMC2747064] [PubMed: 19764095]
- 75.
- Nakagawa M, Sakamoto N, Ueyama M, et al. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol. 2010;45(6):656–65. [PubMed: 20112032]
- 76.
- Nguyen NH, VuTien P, Garcia RT, et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. Journal of Viral Hepatitis. 2010 Oct;17(10):691–7. [PubMed: 20002562]
- 77.
- Arora S, Thornton K, Murata G, et al. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers. N Engl J Med. 2011 Jun;364(23):2199–207. [PMC free article: PMC3820419] [PubMed: 21631316]
- 78.
- Cadranel JF, Boujenah JL, Bourliere M, et al. Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study. Gastroenterologie Clinique et Biologique. 2007 Feb;31(2):180–4. [PubMed: 17347628]
- 79.
- Castera L, Constant A, Henry C, et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2006 Oct 15;24(8):1223–30. [PubMed: 17014581]
- 80.
- Gujral H, Viscomi C, Collantes R. The role of physician extenders in managing patients with chronic hepatitis C. Cleveland Clinic Journal of Medicine. 2004 May;71(Suppl 3):S33–37. [PubMed: 15468616]
- 81.
- Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleveland Clinic Journal of Medicine. 2004 May;71(Suppl 3):S17–21. [PubMed: 15468613]
- 82.
- Pearlman BL. Hepatitis C treatment update. American Journal of Medicine. 2004 Sep 1;117(5):344–52. [PubMed: 15336584]
- 83.
- Scottish Intercollegiate Guidelines Network (SIGN). Management of hepatitis C A national clinical guideline. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network (SIGN); 2006.
- 84.
- Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001 Apr;20(3 Suppl):21–35. [PubMed: 11306229]
- 85.
- Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011. [Accessed March 11, 2011]. www
.ohri.ca/programs /clinical_epidemiology/oxford.asp. - 86.
- Bland JM, Altman DG. Statistics notes The odds ratio. BMJ. 2000 May 27;320(7247):1468. [PMC free article: PMC1127651] [PubMed: 10827061]
- 87.
- Agency for Healthcare Research and Quality’s Effective Health Care Program. Medication Adherence Interventions: Comparative Effectiveness. Rockville, MD: 2012.
- 88.
- Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions. J Clin Epidemiol. 2010 May;63(5):513–23. [PubMed: 19595577]
- 89.
- Atkins D, Chang S, Gartlehner G, et al. Assessing applicability when comparing medical interventions. J Clin Epidemiol. 2011 Nov;64(1198):1207. [PubMed: 21463926]
- 90.
- Alam I, Stainbrook T, Cecil B, et al. Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Alimentary Pharmacology & Therapeutics. 2010 Aug;32(4):535–42. [PubMed: 20500732]
- 91.
- Cacoub P, Ouzan D, Melin P, et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World Journal of Gastroenterology. 2008 Oct 28;14(40):6195–203. [PMC free article: PMC2761581] [PubMed: 18985810]
- 92.
- Curcio F, Di MF, Capraro C, et al. Together... to take care: multidisciplinary management of hepatitis C virus treatment in randomly selected drug users with chronic hepatitis. Journal of Addiction Medicine. 2010 Dec;4(4):223–32. [PubMed: 21769040]
- 93.
- Hussein M, Benner JS, Lee D, et al. Propensity score matching in the evaluation of drug therapy management programs: an illustrative analysis of a program for patients with hepatitis C virus. Qual Manag Health Care. 2010 Jan;19(1):25–33. [PubMed: 20042931]
- 94.
- Larrey D, Salse A, Ribard D, et al. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alpha2a and Ribavirin. Clinical Gastroenterology and Hepatology. 2011;9(9):781–5. [PubMed: 21683161]
- 95.
- Liu SS, Schneekloth TD, Talwalkar JA, et al. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep;44(8):e178–e185. [PubMed: 20495464]
- 96.
- Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics. 2010 Sep;51(5):401–8. [PMC free article: PMC2994596] [PubMed: 20833939]
- 97.
- Ramsey SE, Engler PA, Stein MD, et al. Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. J Addict Res Ther. 2011 May 13;2(2):2–10. [PMC free article: PMC3130194] [PubMed: 21743837]
- 98.
- Bruce RD, Eiserman J, Acosta A, et al. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. American Journal of Drug & Alcohol Abuse. 2012 May;38(3):206–12. [PMC free article: PMC5573865] [PubMed: 22242700]
- 99.
- Patel K, Dev A. Adherence to antiviral therapy in chronic hepatitis C. Current Hepatitis Reports. 2004 Mar 1;3(1):10–5.
- 100.
- Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012 Jun 5;156(11):817–284. W. [PMC free article: PMC4044043] [PubMed: 22393036]
- 101.
- Staines GL, Cleland CM. Observational studies versus randomized controlled trials of behavioral interventions in field settings. Review of General Psychology. 2012;16(1):37–58.
- 102.
- Jepsen PF, Johnsen SP FAU, Gillman MW FAU, et al. Interpretation of observational studies. Heart. 2004. 1468-201X [Electronic] [PMC free article: PMC1768356] [PubMed: 15253985]
- 103.
- Williamson E, Morley R, Lucas A, et al. Propensity scores: From naive enthusiasm to intuitive understanding. Stat Methods Med Res. 2012 Jun;21(3):273–93. [PubMed: 21262780]
- 104.
- Vrijens B, De GS, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012 May;73(5):691–705. [PMC free article: PMC3403197] [PubMed: 22486599]
- 105.
- Bruce RD. Effective Treatment of Hepatitis C in Substance Users. 2008. http://clinicaltrials.gov/ct2/show/NCT00633243.
- 106.
- Klein MB, Cooper C, Brouillette MJ, et al. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemporary Clinical Trials. 2008 Jul;29(4):617–30. [PubMed: 18262853]
- 107.
- Litwin AH, Berg KM, Li X, et al. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. BMC Infect Dis. 2011 Nov 12;11:315. [PMC free article: PMC3227608] [PubMed: 22078241]
- 108.
- North CS. Psychoeducation for Hepatitis and Alcohol Behaviors. 2008. http://clinicaltrials.gov/ct2/show/NCT00598416.
- 109.
- Shun SS. Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection. 2012. http://clinicaltrials.gov/ct2/show/NCT01572233.
- 110.
- Sulkowski M. Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs). 2011. http://clinicaltrials.gov/ct2/show/NCT01448915.
- 111.
- Weiss JJ, Ferrando SJ. Armodafinil for Patients Starting Hepatitis C Virus Treatment. 2011. http://clinicaltrials.gov/ct2/show/NCT01470651.
- References - Interventions to Improve Patient Adherence to Hepatitis C Treatment...References - Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness
Your browsing activity is empty.
Activity recording is turned off.
See more...